A Study of Amivantamab and FOLFIRI Versus Cetuximab/​Bevacizumab and FOLFIRI in Participants With KRAS/​NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3)